Wednesday, October 16, 2019 3:14:45 PM
WEST PALM BEACH, FL, Oct. 16, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Ozop Surgical Corp. (OZSC), a provider of premium surgical devices in the rapidly growing field of minimally invasive spine surgery (“Ozop” or the “Company”), today released the following corporate update on its recent progress and current developments. Ozop believes the license agreement with Spinal Resources, Inc. is exceeding Company expectations.
Some of the specific developments include:
· 3 new surgeons currently using its licensed products, with 2 more expected to schedule cases before year end.
· 2 new Distributors in the contract finalization stage, ramp up expected to start by year end.
· 3 hospital contracts, including one national agreement, in the finalization stage. Cases starting upon approval possibly as soon as December.
· 3 new product introductions, the first, a proprietary MIS system before the end of year.
· First member of its surgeon advisory board has joined, more updates to follow.
Michael Chermak, Chief Executive Officer of OZOP, commented, “Our primary objective is to achieve operational profitability at the earliest moment possible. Our path to this goal will be accomplished by a combination of maximizing current sales opportunities and reducing overhead wherever possible, and investing in inventory and product development to support our growing sales pipeline.”
About Ozop Surgical Corp.
Ozop Surgical, Corp. (www.ozopsurgical.com) invents, designs, develops, manufactures and distributes innovative endoscopic instruments, surgical implants, instrumentation, devices and related technologies, focused on spine, neurological and pain management procedures and specialties. Our focus is on economically disrupting the market with clinically equivalent or superior existing and new products resulting in immediate and significant savings for providers, payors and consumers. For more information please visit www.ozopsurgical.com.
Recent OZSC News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/29/2024 05:15:18 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/23/2024 09:59:05 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/12/2024 09:56:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 08:15:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:00:50 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 03:33:21 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/07/2023 09:28:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2023 09:24:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM